[go: up one dir, main page]

MX2021002349A - Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario. - Google Patents

Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.

Info

Publication number
MX2021002349A
MX2021002349A MX2021002349A MX2021002349A MX2021002349A MX 2021002349 A MX2021002349 A MX 2021002349A MX 2021002349 A MX2021002349 A MX 2021002349A MX 2021002349 A MX2021002349 A MX 2021002349A MX 2021002349 A MX2021002349 A MX 2021002349A
Authority
MX
Mexico
Prior art keywords
patients
plasma kallikrein
hereditary angioedema
prior
kallikrein inhibitors
Prior art date
Application number
MX2021002349A
Other languages
English (en)
Inventor
Peng Lu
Christina Nurse
Xinming Hao
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2021002349A publication Critical patent/MX2021002349A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan en la presente métodos para tratar y prevenir ataque de angioedema hereditaria en ciertas subpoblaciones de pacientes humanos utilizando anticuerpo que se unen a la calicreina plasmática activa con regímenes de tratamiento específicos, por ejemplo, a aproximadamente 300 mg cada dos semanas. Las subpoblaciones de pacientes humanos ejemplares incluyen pacientes femeninos, pacientes de menos de 18 años de edad, entre 40 y menos de 65 años de edad, pacientes adolescentes, pacientes quienes han tenido uno o más ataques laríngeos previos, pacientes quienes han tenido entre 1 y 2, 2 y 3, o más de 3 ataques de HAE en las cuatro semanas antes de la primera dosis del primer período de tratamiento; y/o ha recibido tratamiento con un inhibidor de C1 antes del primer período de tratamiento.
MX2021002349A 2018-08-30 2019-08-30 Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario. MX2021002349A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862725216P 2018-08-30 2018-08-30
US201962808612P 2019-02-21 2019-02-21
PCT/US2019/048961 WO2020047352A1 (en) 2018-08-30 2019-08-30 Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack

Publications (1)

Publication Number Publication Date
MX2021002349A true MX2021002349A (es) 2021-05-31

Family

ID=67953889

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002349A MX2021002349A (es) 2018-08-30 2019-08-30 Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.

Country Status (12)

Country Link
US (2) US20200109214A1 (es)
EP (1) EP3843840A1 (es)
JP (2) JP7585193B2 (es)
KR (1) KR20210053928A (es)
CN (1) CN113056304A (es)
AU (2) AU2019328324B2 (es)
BR (1) BR112021003789A2 (es)
CA (1) CA3110689A1 (es)
IL (1) IL281063A (es)
MA (1) MA53490A (es)
MX (1) MX2021002349A (es)
WO (1) WO2020047352A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102502293B1 (ko) 2011-01-06 2023-02-21 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
CN118406688A (zh) 2013-03-15 2024-07-30 武田药品工业株式会社 抗血浆激肽释放酶抗体
PL3096798T3 (pl) 2014-01-21 2021-07-26 Takeda Pharmaceutical Company Limited Białka wiążące kalikreinę osocza i ich zastosowanie w leczeniu obrzęku naczynioruchowego
CA2942713A1 (en) 2014-03-27 2015-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
WO2017100679A1 (en) 2015-12-11 2017-06-15 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
BR112021003789A2 (pt) * 2018-08-30 2021-05-18 Dyax Corp. método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae
CA3167336A1 (en) * 2020-01-13 2021-07-22 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
CA2180950C (en) 1994-01-11 2005-03-29 William Markland Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
ES2528254T3 (es) 2002-06-07 2015-02-05 Dyax Corp. Polipéptidos de dominio Kunitz modificado y su uso para reducir la isquemia o el inicio de una respuesta inflamatoria sistémica asociada con un procedimiento quirúrgico
KR102502293B1 (ko) * 2011-01-06 2023-02-21 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
CN118406688A (zh) * 2013-03-15 2024-07-30 武田药品工业株式会社 抗血浆激肽释放酶抗体
CA2942713A1 (en) * 2014-03-27 2015-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
AU2016243160B2 (en) * 2015-03-30 2022-02-24 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
WO2017100679A1 (en) 2015-12-11 2017-06-15 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
JP6885952B2 (ja) * 2015-12-18 2021-06-16 グラコ ミネソタ インコーポレーテッド ベローズの取付けと保持方法
BR112021003789A2 (pt) * 2018-08-30 2021-05-18 Dyax Corp. método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae

Also Published As

Publication number Publication date
CN113056304A (zh) 2021-06-29
KR20210053928A (ko) 2021-05-12
MA53490A (fr) 2022-05-04
WO2020047352A8 (en) 2020-04-16
EP3843840A1 (en) 2021-07-07
AU2019328324B2 (en) 2025-06-19
US20200109214A1 (en) 2020-04-09
JP2024113183A (ja) 2024-08-21
JP7585193B2 (ja) 2024-11-18
AU2025230807A1 (en) 2025-10-02
JP2021535161A (ja) 2021-12-16
US20230104754A1 (en) 2023-04-06
CA3110689A1 (en) 2020-03-05
IL281063A (en) 2021-04-29
BR112021003789A2 (pt) 2021-05-18
AU2019328324A1 (en) 2021-04-29
WO2020047352A1 (en) 2020-03-05

Similar Documents

Publication Publication Date Title
MX2021002349A (es) Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.
NZ783274A (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
ZA202202361B (en) Treatment of hidradenitis suppurativa using jak inhibitors
MX2025000166A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y metodos de uso del mismo
MY199967A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors
WO2020186132A8 (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
MX2010006519A (es) Metodo para tratar una fractura de hueso con anticuerpos anti-esclerostina.
SG161307A1 (en) Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
TW200630093A (en) Dose forms
AR109103A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
WO2008030538A3 (en) Cancer stem cell-targeted cancer therapy
MX2022006533A (es) Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y metodos de uso del mismo.
MX2023009971A (es) Composicion farmaceutica que contiene anticuerpo anti-tslp.
PH12022550130A1 (en) Enzyme inhibitors
TN2022000185A1 (en) Methods of treating splenomegaly
PH12021553102A1 (en) Methods of treating fabry disease in patients having renal impairment
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
TW200507840A (en) Method of treating multiple myeloma
TN2022000113A1 (en) Dosing regimen for anti-dll3 agents
MX2022014034A (es) Métodos para tratar covid-19 con el uso de bardoxolona metilo o análogos de esta.
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
WO2020243273A3 (en) Methods of treating cholangiocarcinoma
MX2022008649A (es) Inhibidores de calicreina plasmatica y sus usos para tratar episodios de angioedema hereditario pediatrico.